KELIX bio, a pan-African biopharmaceutical platform, has entered into a binding agreement to acquire Moroccan Pharmaceutical Institute (“PHI”).
This investment marks KELIX bio’s first entry into Morocco – an important market in the company’s strategy – at a time when the Kingdom is accelerating the successful rollout of AMO (Assurance Maladie Obligatoire), a far-reaching plan to provide universal health coverage to Moroccans.
Founded in 1988, PHI has expertise in manufacturing, promoting, and importing pharmaceutical products.
UGGC Africa advised Pharmaceutical Institute (PHI) in this agreement with partner Laurent Sablé (pictured).
Naciri & Associés Allen & Overy acted as legal counsel and Sijilmasa (Amine Rezzouk) acted on the financial aspects of the deal.